GlobeNewswire·Nov 10, 2026, 8:05 AM ET

VivoSim Labs to Showcase Multiparametric Human 3D Tissue Safety Data at the American College of Toxicology (ACT) 47th Annual Meeting

VIVS

VivoSim Labs (Nasdaq: VIVS) announced its scientific team will present new translational safety data at the American College of Toxicology 47th Annual Meeting in San Antonio, Texas, from November 15–18, 2026.
Presentations will cover data from large multi-compound benchmarks & emerging modalities including small molecules & antibody-drug conjugates (ADCs) to demonstrate clinical safety risk prediction under non-animal testing frameworks.
The company highlighted that its multiparametric approach measures multiple tissue outcomes beyond simple cell death to provide superior predictive power for drug candidates.
Chief Scientific Officer Amar Sethi, M.D., Ph.D. stated the presentations emphasize moving beyond direct cell toxicity to deliver clinically predictive risk stratification for drug-induced liver injury & gastrointestinal toxicity.
VivoSim executive & scientific leadership will be on-site to discuss platform integration & commercial partnerships.
VivoSim Labs operates from San Diego, CA, & focuses on 3D human tissue models of the liver & intestine using new approach methodologies (NAMs).
The company anticipates accelerated adoption of human tissue models following the FDA Roadmap to refine animal testing requirements in favor of non-animal NAM methods.
The press release includes forward-looking statements regarding cash on hand, revenue growth, & marketing progress, noting risks detailed in SEC filings including the Form 10-K filed July 14, 2026, & Form 10-Q filed August 12, 2026.

Company: VivoSim Labs, Inc.
Keywords: Nasdaq:VIVS, VivoSim Labs, Inc., 3D Bioprinting, 3D Tissue Safety Data, VIVS, ACT 2026, Vivosim, NAMkind services, NAM Models, NAMs, Liver, Gastrointestinal Toxicity